Compositions and methods for treating diseases of the liver

Abstract

An inhibitory nucleic molecule that targets cyclin D1 mRNA is described. Generally, the inhibitory nucleic acid molecule includes a nucleotide sequence that is complementary to at least a portion of SEQ ID NO:1. In one or more embodiments, the inhibitory nucleic acid molecule is complementary to nucleotides 330-350 of SEQ ID NO:1, nucleotides 372-392 of SEQ ID NO:1, nucleotides 525-545 of SEQ ID NO:1, nucleotides 801-825 of SEQ ID NO:1, nucleotides 1206-1230 of SEQ ID NO:1 or nucleotides 2416-2440 of SEQ ID NO:1. The inhibitory nucleic acid molecule can include RNA, DNA, or both. In another aspect, a method of treating a disease of the liver in a subject having, or at risk of having, a disease of the liver generally includes administering to the subject a composition that includes an amount of an inhibitor of cyclin D1 effective to ameliorate at least one symptom or clinical sign of the disease of the liver.

Dependencies are inferred from the claim text.